SAR 31.95
(2.4%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 19.53 Million SAR | -59.09% |
2022 | 47.74 Million SAR | 41.63% |
2021 | 34.51 Million SAR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 23.12 Million SAR | 34.91% |
2023 Q2 | 26.8 Million SAR | 0.68% |
2023 Q4 | 16.61 Million SAR | -38.0% |
2023 FY | - SAR | -59.09% |
2022 Q2 | 19.51 Million SAR | 0.0% |
2022 FY | - SAR | 41.63% |
2022 Q4 | 26.62 Million SAR | 36.44% |
2021 FY | - SAR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 85.13 Million SAR | 77.057% |
Al-Dawaa Medical Services Company | 830.43 Million SAR | 97.648% |
Nahdi Medical Company | 1.64 Billion SAR | 98.812% |
Al-Razi Medical Co. | 5.64 Million SAR | -245.718% |